おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Fortress Biotech
company
About
Fortress Biotech is biopharmaceutical company focused on acquiring, developing, and commercializing drugs and drug candidates.
- 51 - 100
Highlights
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $15M
- Industries
- Biotechnology,Health Care,Life Science,Pharmaceutical
- Founded date
- Jan 1, 2006
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Fortress Biotech is a biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates. Fortress has 5 marketed products and over 25 programs in development through its majority-owned and majority-controlled partners and at partners it founded and holds significant minority ownership positions. Target therapeutic areas and technologies include oncology, rare diseases, gene and cell therapy, and other areas of high unmet need.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$15M
Fortress Biotech has raised a total of
$15M
in funding over 2 rounds. Their latest funding was raised on
Aug 29, 2012 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 29, 2012 | Post-IPO Debt | $15M | 1 |
Hercules Capital
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Fortress Biotech is funded by 1 investors.
Hercules Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
